Lamivudine/tenofovir disoproxil

Lamivudine/tenofovir
Combination of
Lamivudine	Nucleoside reverse transcriptase inhibitor
Tenofovir disoproxil	Nucleotide reverse transcriptase inhibitor
Clinical data
Trade names	Cimduo, Temixys
AHFS/Drugs.com	Monograph
MedlinePlus	a618039
License data	US DailyMed: Cimduo;
Routes of; administration	By mouth
ATC code	J05AR12 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
KEGG	D11395;

Lamivudine/tenofovir disoproxil, sold under the brand name Cimduo among others, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS in adults and children weighing more than 35 kilograms (77 lb).^[1]^[3] It contains lamivudine and tenofovir disoproxil.^[1] It is taken by mouth.^[1]

Lamivudine/tenofovir was approved for medical use in the United States in February 2018.^[1]^[4]

References

^ ^a ^b ^c ^d ^e "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.
^ "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 13 February 2022.
^ Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.
^ "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.

External links

"Lamivudine". Drug Information Portal. U.S. National Library of Medicine.
"Tenofovir disoproxil". Drug Information Portal. U.S. National Library of Medicine.
"Tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

Zdroj:https://en.wikipedia.org?pojem=Lamivudine/tenofovir_disoproxil
Text je dostupný za podmienok Creative Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších podmienok. Podrobnejšie informácie nájdete na stránke Podmienky použitia.

[Cimduo_FDA_label-1] "Cimduo- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. 22 March 2018. Retrieved 26 March 2020.

[Temixys_FDA_label-2] "Temixys- lamivudine and tenofovir disoproxil fumarate tablet, film coated". DailyMed. Retrieved 13 February 2022.

[Waters_2021-3] Waters L, Mehta V, Gogtay J, Boffito M (March 2021). "The evidence for using tenofovir disoproxil fumarate plus lamivudine as a nucleoside analogue backbone for the treatment of HIV". Journal of Virus Eradication. 7 (1): 100028. doi:10.1016/j.jve.2021.100028. PMC 7868802. PMID 33598310.

[4] "Drug Approval Package: Cimduo (lamivudine and tenofovir disoproxil fumarate)". U.S. Food and Drug Administration (FDA). 27 November 2018. Retrieved 26 March 2020.

[1]

[2]

[3]

[4]

References

Further reading

External links